Knowledge, Attitudes, and Practices Regarding Meningococcal B Vaccination Since the 2015 Recommendation: A Review.

The United States Advisory Committee on Immunization Practices recommends routine vaccination against meningococcal serogroups A, C, W, and Y for all aged 11-12 years (with a booster dose for age 16 years) and vaccination against meningococcal serogroup B (MenB) for ages 16-23 years under shared clinical decision-making (SCDM). Considering the Advisory Committee on Immunization Practices' ongoing revision of the adolescent meningococcal vaccine schedule, it is important to capture the perspectives of key stakeholders (adolescents and young adults, parents, and health-care providers) in order to understand barriers to meningococcal vaccination. We conducted a targeted literature search and narrative review of survey-based studies to consolidate available evidence on knowledge, attitudes, and practices among these stakeholders since the MenB recommendation in 2015.

Late-onset unexplained seizures are associated with cognitive impairment and lower amygdala volumes.

Late-onset epilepsy has been linked with accelerated cognitive decline and a higher risk of dementia. In this study, we sought to characterize the cognitive profile of participants with late-onset unexplained epilepsy and compare their MRI findings to healthy controls, to better understand underlying disease mechanisms. We recruited participants with at least one new-onset unexplained seizure at age 55 or later, without cortical lesions on MRI, within 5 years of the first seizure.

Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohorts.

Brain network dynamics have been extensively explored in patients with subjective cognitive decline (SCD). However, these studies are susceptible to individual differences, scanning parameters, and other confounding factors. Therefore, how to reveal subtle SCD-related subtle changes remains unclear.

Validation of the multi-day Boston remote assessment of neurocognitive health (BRANCH) among cognitively impaired & unimpaired older adults.

Background: The multi-day Boston Remote Assessment of Neurocognitive Health (BRANCH) is a remote, web-based assessment designed to capture the earliest cognitive changes in the preclinical stage of Alzheimer's disease (AD). It has been validated in unimpaired older adults, but as individuals progress on the AD continuum, assessments need to remain feasible and valid at different clinical stages. The focus of this study was to assess feasibility and validity of multi-day BRANCH in participants with and without cognitive impairment.

Detecting early cognitive deficits in preclinical Alzheimer's disease using a remote digital multi-day learning paradigm.

Remote, digital cognitive testing on an individual's own device provides the opportunity to deploy previously understudied but promising cognitive paradigms in preclinical Alzheimer's disease (AD). The Boston Remote Assessment for NeuroCognitive Health (BRANCH) captures a personalized learning curve for the same information presented over seven consecutive days. Here, we examined BRANCH multi-day learning curves (MDLCs) in 167 cognitively unimpaired older adults (age = 74.